Resveratrol: An assessment of its dose response an introduction

Anti-atherogenic effects of resveratrol

(2010) V R Ramprasath et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

BELLE: An evolving legacy

(2010) Edward J Calabrese   HUMAN & EXPERIMENTAL TOXICOLOGY

Hormesis in high-throughput screening of antibacterial compounds in E coli

(2010) Edward J Calabrese et al.   HUMAN & EXPERIMENTAL TOXICOLOGY

trans-Resveratrol Reduces Precancerous Colonic Lesions in Dimethylhydrazine-Treated Rats

(2010) Irene Alfaras et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases

(2010) Albert Y. Sun et al.   MOLECULAR NEUROBIOLOGY

A possibility of nutriceuticals as an anti-aging intervention: Activation of sirtuins by promoting mammalian NAD biosynthesis

(2010) Shin-ichiro Imai   PHARMACOLOGICAL RESEARCH

Getting the dose–response wrong: why hormesis became marginalized and the threshold model accepted

(2009) Edward J. Calabrese   ARCHIVES OF TOXICOLOGY

The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment

(2009) Edward J. Calabrese   ARCHIVES OF TOXICOLOGY

Resveratrol as a Health and Disease Benefit Agent

(2009) İsmail Tosun et al.   FOOD REVIEWS INTERNATIONAL

Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis

(2009) Nabiha Yusuf et al.   MOLECULAR CARCINOGENESIS

Hormesis Predicts Low-Dose Responses Better Than Threshold Models

(2008) Edward J. Calabrese et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY